The aim of the present study was the investigation of the pharmacokinetics of bismuth after application of different preparations of colloid bismuth subcitrate (CBS; CAS 57644-54-9). 6 healthy volunteers were recommended to take a solution containing 240 mg CBS b.d. before breakfast and before the evening meal for 2 weeks, whereas 6 other volunteers received tablets containing 120 mg CBS 2 b.d. In both groups resulting daily CBS dose was 480 mg. On day 7 and day 14, 24 h urine excretion of bismuth was found to be significantly lower after application of the solution as compared to the one after application of the tablet (day 7: solution 110 micrograms/day--table 872 micrograms/day; day 14: solution 133 micrograms/day--table 872 micrograms/day; p < 0.05). After a single dose of 240 mg of CBS plasma AUC amounted to 42.8 micrograms/ml.h and 4.2 micrograms/ml.h after application of the tablet and the solution, respectively. Our results demonstrate that systemic bismuth load is markedly lower after application of the CBS solution as compared to the CBS tablet.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
In Vitro Susceptibility and Synergistic Effect of Bismuth Against .
Antibiotics (Basel)
October 2024
Institute of New Frontier Research, Hallym University College of Medicine, Chuncheon 24252, Gangwon-do, Republic of Korea.
Bismuth is commonly used in () eradication therapy. However, few studies have examined the in vitro susceptibility of to bismuth. Moreover, the exact mechanism of action of bismuth on remains unclear.
View Article and Find Full Text PDFTegoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Prospective, Randomized, Multicenter Study in Fujian, China.
Helicobacter
November 2024
Department of Gastroenterology, The Shengli Clinical Medical College, Fujian Medical University, Fuzhou, China.
Introduction: Few studies have investigated the efficacy and safety of tegoprazan-amoxicillin (TA) dual therapy for Helicobacter pylori eradication. We aim to evaluate the effectiveness and safety of different dosages of TA dual therapy for H. pylori eradication.
View Article and Find Full Text PDFGastrodenol suppresses NLRP3/GSDMD mediated pyroptosis and ameliorates inflammatory diseases.
Cell Immunol
November 2024
Department of Neurology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China; State Key Laboratory of Pharmaceutical Biotechnology and Institute of Translational Medicine for Brain Critical Diseases, Nanjing University, Nanjing, China; Jiangsu Key Laboratory for Molecular Medicine, Medical School of Nanjing University, Nanjing, China. Electronic address:
Pyroptosis, a form of inflammatory programmed cell death, plays a pivotal role in the pathogenesis of various diseases. This process is primarily mediated by the nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing protein 3 (NLRP3). Gastrodenol (Bismuth tripotassium dicitrate, GAS) is a mineral compound which is used to treat duodenal and gastric ulcers associated with Helicobacter pylori.
View Article and Find Full Text PDFComparison of Amoxicillin Administered Twice versus Four Times a Day in First-Line Eradication Using Tegoprazan, Clarithromycin, and Bismuth: A Propensity Score Matching Analysis.
Microorganisms
September 2024
Department of Pathology, Soonchunhyang University Hospital, Yongsan-gu, Seoul 04401, Republic of Korea.
This study aimed to investigate the effects of different amoxicillin (AMX) dosing schedules on bismuth quadruple therapy in treatment-naïve patients. A total of 139 -infected patients received a 2-week eradication regimen consisting of 50 mg tegoprazan, 500 mg clarithromycin, and 300 mg bismuth tripotassium dicitrate twice daily, 1000 mg AMX twice daily (BID group), or 500 mg AMX four times daily (QID group). We performed a urea breath test to evaluate eradication eight weeks after treatment and compared the eradication rate, patient compliance, and adverse drug events between the BID and QID groups.
View Article and Find Full Text PDFEfficacy of Bismuth Therapy in Eradicating Helicobacter pylori in Children-Data From the RENIHp Registry.
Helicobacter
October 2024
Pediatric Gastroenterology Unit, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain.
Article Synopsis
- The study aimed to evaluate the effectiveness of colloidal bismuth subcitrate (CBS) in eliminating H. pylori infections in children aged 5-18, using data from a national pediatric registry.
- Out of 682 patients in the registry, 38 were treated with CBS, and 93.8% of those treated successfully eradicated the infection, showing better results compared to non-CBS treatments.
- The findings indicate that CBS therapies can be highly effective even in patients with prior unsuccessful treatments, although they were used in a limited scope and at lower-than-ideal dosages.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!